Ben Zeskind from Immuneering highlights how prioritizing survival over rapid tumor shrinkage can result in better pancreatic cancer treatment outcomes.



Summary

Ben Zeskind of Immuneering argues that the current focus on shrinking pancreatic tumors in clinical trials is misguided and may not translate to improved patient survival. He suggests a shift in focus towards treatments that prioritize prolonging life, even if they don’t dramatically shrink tumors. Zeskind believes that focusing solely on tumor shrinkage can lead to the rejection of potentially life-extending therapies that may work by slowing tumor growth or improving overall patient health without causing significant reduction in size. Ultimately, he advocates for a more nuanced approach that prioritizes survival as the key metric for success in pancreatic cancer treatment.

Read more…

This post is part of “Science and Technology News”, Follow for more…!!!

Credits: Source

Disclaimer